Evidence map›Paper›PMID 32580646›Full record

ReviewTherapeutic advances in cardiovascular disease

Current status of white coat hypertension: where are we?

Gani Nuredini, Alec Saunders, Chakravarthi Rajkumar, Michael Okorie

Open access · goldAbstract readReview
In one paragraph

Review in Therapeutic advances in cardiovascular disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.

  1. Pooled it
  2. Cardiovascular frailty - an emerging frailty phenotype.Journal of human hypertension · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Prevalence of hypertension and related factors among suspected hypertensive medical personnel during COVID-19 vaccination.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  7. Article
  8. Review
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. White coat hypertension in acute retinal vein occlusion.International journal of retina and vitreous · 2024
    Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Gani NurediniDepartment of Medicine, Brighton and Sussex Medical School, Brighton, UK.ORCID https://orcid.org/0000-0001-5971-9843
Alec SaundersDepartment of Medicine, Brighton and Sussex Medical School, Brighton, UK.ORCID https://orcid.org/0000-0003-4303-7690
Chakravarthi RajkumarDepartment of Medicine, Brighton and Sussex Medical School, Brighton, UK.
Michael OkorieDepartment of Medicine, Brighton and Sussex Medical School, Watson Building (Room 344), Falmer, Brighton, BN1 9PH, UK.ORCID https://orcid.org/0000-0003-1960-8860
Brighton and Sussex Medical School · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

White coat hypertension (WCH) is characterised by an elevated clinic blood pressure (BP) with normal ambulatory or home BP. It is well recognised in clinical practice and occurs in approximately one-third of untreated patients with elevated clinic BP. Current evidence suggests that WCH is associated with cardiovascular risk factors, including the development of sustained hypertension and the presence of target organ damage. However, its effects on cardiovascular outcomes remain a matter of debate. There is also insufficient evidence from randomised controlled trials to determine whether WCH warrants treatment. This narrative review aims to provide an update on the current understanding of WCH. It focuses on the clinical characteristics and potential implications of WCH, its relationship to cardiovascular risk and the evidence regarding treatment. Gaps in existing research are also highlighted.

Indexed as

Blood PressureAntihypertensive AgentsBlood Pressure DeterminationDisease ProgressionHumansOffice VisitsPhenotypeRisk FactorsTreatment OutcomeWhite Coat HypertensionAntihypertensive Agentscardiovascular risktarget organ damagewhite coat hypertension

Identifiers

PMID32580646
PMCPMC7318827
OpenAlexW3037030280

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.